Can-Fite’s Namodenoson Gains FDA Orphan Status
Company Announcements

Can-Fite’s Namodenoson Gains FDA Orphan Status

Can-Fite BioPharma (CANF) has released an update.

Can-Fite BioPharma Ltd., a biotech firm targeting oncological and inflammatory diseases, announced that its drug Namodenoson received Orphan Drug Designation from the FDA for pancreatic cancer treatment, signaling regulatory advantages and potential market exclusivity. The company is gearing up for a Phase II trial to assess the drug’s safety and effectiveness in patients with advanced pancreatic cancer. Namodenoson has previously shown promise in Phase II trials for liver cancer and has a strong safety profile based on clinical studies.

For further insights into CANF stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCan-Fite BioPharma Advances in Pancreatic Cancer Trial
TheFlyCan-Fite BioPharma doses first patient in Phase IIa trial
TipRanks Auto-Generated NewsdeskCan-Fite BioPharma Secures Australian Patent for Obesity Drug
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App